|Stage||Description||5-Year Survival Rate|
|IA||Tumor is limited to the inner layer of the stomach||71 percent|
|IB||Tumor is limited to the inner layer of the stomach||57 percent|
|IIA||Tumor has spread to the main muscle layer of the stomach||45 percent|
|IIB||Tumor has spread to the main muscle layer of the stomach||33 percent|
|IIIA||Tumor has spread to the outer layers of the stomach, to nearby lymph nodes and into nearby organs||20 percent|
|IIIB||Tumor has spread to the outer layers of the stomach, to nearby lymph nodes and into nearby organs||14 percent|
|IIIC||Tumor has spread to the outer layers of the stomach, to nearby lymph nodes and into nearby organs||9 percent|
|IV||Tumor has spread to organs and lymph nodes distant from the stomach||4 percent|
2 National Cancer Institute. Surveillance Epidemiology and End Results Stomach Cancer Fact Sheet. http://seer.cancer.gov/statfacts/html/stomach.html. Accessed March 15, 2010.
3 American Cancer Society. Stomach Cancer Detailed Guide. http://www.cancer.org. Accessed March 15, 2010.
4 Bang Y, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol, 2009 ASCO Meeting Proceedings; 27:15s (supplement; abstr 4556).
5 Moiseyenko VM, et al. Randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-flourouracil (F) to CF in patients with metastatic gastric adenocarcinoma (MGC). J Clin Oncol, 2005 ASCO Meeting Proceedings; 23:16s (supplement; abstr 4002).